CSL Gelecekteki Büyüme

Future kriter kontrolleri 1/6

CSL kazanç ve gelirin sırasıyla yıllık 13.1% ve 6.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 13.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 18.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

13.1%

Kazanç büyüme oranı

13.2%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.0%
Gelir büyüme oranı	6.5%
Gelecekteki özkaynak getirisi	18.5%
Analist kapsamı	Good
Son güncelleme	03 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

OTCPK:CMXH.F - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2027	18,038	4,129	4,108	4,962	14
6/30/2026	16,902	3,628	3,590	4,371	15
6/30/2025	15,772	3,097	2,967	3,792	15
6/30/2024	14,800	2,642	1,506	2,764	N/A
3/31/2024	14,490	2,557	1,332	2,727	N/A
12/31/2023	14,179	2,472	1,158	2,690	N/A
9/30/2023	13,745	2,333	1,034	2,646	N/A
6/30/2023	13,310	2,194	909	2,601	N/A
3/31/2023	12,507	2,156	765	2,392	N/A
12/31/2022	11,705	2,118	622	2,182	N/A
9/30/2022	11,133	2,186	1,001	2,406	N/A
6/30/2022	10,562	2,255	1,381	2,629	N/A
3/31/2022	10,587	2,290	1,251	2,679	N/A
12/31/2021	10,612	2,325	1,121	2,728	N/A
9/30/2021	10,461	2,350	1,538	3,175	N/A
6/30/2021	10,310	2,375	1,955	3,622	N/A
3/31/2021	10,145	2,520	2,127	3,597	N/A
12/31/2020	9,980	2,665	2,299	3,571	N/A
9/30/2020	9,565	2,384	1,710	3,030	N/A
6/30/2020	9,151	2,103	1,121	2,488	N/A
3/31/2020	9,048	2,054	1,009	2,418	N/A
12/31/2019	8,944	2,006	897	2,347	N/A
9/30/2019	8,742	1,962	628	1,996	N/A
6/30/2019	8,539	1,919	360	1,644	N/A
3/31/2019	8,406	1,861	426	1,621	N/A
12/31/2018	8,274	1,803	492	1,597	N/A
9/30/2018	8,094	1,766	701	1,750	N/A
6/30/2018	7,915	1,729	910	1,902	N/A
3/31/2018	7,666	1,674	N/A	1,662	N/A
12/31/2017	7,417	1,618	N/A	1,422	N/A
9/30/2017	7,182	1,478	N/A	1,335	N/A
6/30/2017	6,947	1,337	N/A	1,247	N/A
3/31/2017	6,802	1,333	N/A	1,192	N/A
12/31/2016	6,656	1,329	N/A	1,138	N/A
9/30/2016	6,386	1,286	N/A	1,158	N/A
6/30/2016	6,115	1,242	N/A	1,179	N/A
3/31/2016	5,983	1,324	N/A	1,296	N/A
12/31/2015	5,850	1,406	N/A	1,413	N/A
9/30/2015	5,654	1,392	N/A	1,388	N/A
6/30/2015	5,459	1,379	N/A	1,364	N/A
3/31/2015	5,482	1,366	N/A	1,434	N/A
12/31/2014	5,505	1,354	N/A	1,504	N/A
9/30/2014	5,420	1,330	N/A	1,432	N/A
6/30/2014	5,335	1,307	N/A	1,361	N/A
3/31/2014	5,189	1,270	N/A	1,257	N/A
12/31/2013	5,042	1,233	N/A	1,154	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CMXH.F 'nin tahmini kazanç büyümesi (yıllık 13.1% ) tasarruf oranının ( 2.6% ) üzerindedir.

Kazançlar ve Piyasa: CMXH.F şirketinin kazançlarının (yıllık 13.1% ) US pazarından (yıllık 15.4% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: CMXH.F şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: CMXH.F şirketinin gelirinin (yıllık 6.5% ) US pazarından (yıllık 8.9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CMXH.F şirketinin gelirinin (yıllık 6.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CMXH.F 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 18.5 %).

CSL Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited Provides Financial Guidance for Fiscal 2022

Recent updates

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.

CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.

Vifor Pharma and CSL Confirm Merger Talks

Centerview Reportedly Role in Vifor Sale

Vifor Says Regularly in Talks with Other Market Participants After Reports

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

CSL Limited Provides Financial Guidance for Fiscal 2022

Seqirus Announces Health Canada Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older

CSL Limited to Report First Half, 2021 Results on Feb 18, 2021

CSL Limited Announces Resignation of Pascal Soriot from the Position of Non-Executive Director, Effective 1 February 2021

CSL Limited Announces Management Changes

CSL Limited (ASX:CSL) completed the acquisition of Vitaeris Inc.

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin